SCHEMBL5356280

SCHEMBL5356280

CCN(c1ccc(F)cc1)S(=O)(=O)c1ccsc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
TSHR P16473 2/20 0.51
MAPK1 P28482 2/20 0.51
HSD17B10 Q99714 1/20 0.51
LMNA P02545 6/20 0.48
POLB P06746 3/20 0.44
ESR1 P03372 2/20 0.44
NSD2 O96028 1/20 0.44
APEX1 P27695 1/20 0.44
RECQL P46063 1/20 0.44
ESR2 Q92731 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
FABP4 P15090 3/20 0.44
NPSR1 Q6W5P4 1/20 0.43
TP53 P04637 2/20 0.42
THRB P10828 1/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.41
FABP3 P05413 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5354492 0.86 LMNA (0.64) KMT2ALMNAPOLBTP53THRB
SCHEMBL3821615 0.77 LMNA (0.58) KMT2ATSHRHSD17B10LMNAPOLB
SCHEMBL5356604 0.74 LMNA (0.46) KMT2ATSHRLMNAFABP4NPSR1
SCHEMBL534172 0.74 POLB (0.60) TSHRLMNAPOLBESR1NSD2
SCHEMBL5361944 0.73 AOC3 (0.45) KMT2ATSHRLMNAFABP4NPSR1
SCHEMBL16346833 0.72 LMNA (0.64) KMT2ATSHRLMNAFABP4NPSR1
SCHEMBL2531253 0.68 LMNA (0.68) KMT2ATSHRLMNAFABP4NPSR1
SCHEMBL5356271 0.68 TAAR1 (0.50) KMT2ATSHRLMNAPOLBTDP1
SCHEMBL5352376 0.67 LMNA (0.38) LMNAPOLBFABP4NPSR1MAPT
SCHEMBL15316363 0.67 LMNA (0.57) KMT2ATSHRLMNAL3MBTL1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 KMT2A 649/4885TSHR 284/4885MAPK1 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.